Improvement of high serum levels of biomarkers of endothelial injury after allogeneic hematopoietic SCT with pre-existing severe hepatitis using recombinant human soluble thrombomodulin

Bone Marrow Transplant. 2014 Nov;49(11):1444-5. doi: 10.1038/bmt.2014.156. Epub 2014 Jul 28.

Authors

T Saito¹, Y Inoue¹, K Sato¹, Y Tsuruoka¹, R Shigefuku², H Ikeda², C Okuse², M Takahashi¹, I Miura¹

Affiliations

¹ Division of Hematology and Oncology, Department of Internal Medicine, St Marianna University of Medicine, Kawasaki, Japan.
² Division of Gastroenterology and Hepatology, Department of Internal Medicine, St Marianna University of Medicine, Kawasaki, Japan.

PMID: 25068421
DOI: 10.1038/bmt.2014.156

No abstract available

Publication types

Case Reports
Letter
Research Support, N.I.H., Intramural

MeSH terms

Allografts
Biomarkers / blood
Endothelium, Vascular / injuries*
Hematopoietic Stem Cell Transplantation*
Hepatic Veno-Occlusive Disease* / blood
Hepatic Veno-Occlusive Disease* / etiology
Hepatic Veno-Occlusive Disease* / prevention & control
Hepatitis* / blood
Hepatitis* / complications
Hepatitis* / therapy
Humans
Male
Middle Aged
Pancytopenia / blood
Pancytopenia / complications
Pancytopenia / therapy
Thrombomodulin / administration & dosage*

Substances

Biomarkers
THBD protein, human
Thrombomodulin

Grants and funding

Intramural NIH HHS/United States